about
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this imm...
Read More
40.47
0.70
(1.76%)
1.1M
XNAS Volume
XNAS 15 Oct, 2026 10:49 AM (EDT)
Board Meeting
The next board meeting for Sanofi (ADR) is on 23 Oct 2026 for the purpose of Sanofi SA Third Quarter Earnings Results for 2026
See details
Low Financial Strength
Mid Valuation
Technically Bearish
Weak Stock
These stocks have weak financials and momentum. Buying interest is low. While the stock is affordable, investors should exercise caution
View Similar
Embed DVM
Sanofi (ADR) Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..